VABYSMO

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Ecuador, France, Ireland, Israel, Italy, Japan, Lithuania, Nigeria, Romania, UK.

Active ingredients

The drug VABYSMO contains one active pharmaceutical ingredient (API):

1	Faricimab UNII QC4F7FKK7I - FARICIMAB
	Faricimab is a humanised bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of two distinct pathways by neutralisation of both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). By dual inhibition of Ang-2 and VEGF-A, faricimab reduces vascular permeability and inflammation, inhibits pathological angiogenesis and restores vascular stability.
	Read more about Faricimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VABYSMO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01LA09		S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02527618
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	238-MBE-1122
FR	Base de données publique des médicaments	61150655
IL	מִשְׂרַד הַבְּרִיאוּת	9261
IT	Agenzia del Farmaco	050231012
JP	医薬品医療機器総合機構	1319408A1020
LT	Valstybinė vaistų kontrolės tarnyba	1095545
NG	Registered Drug Product Database	A6-100124
Switch country to Nigeria in order to find specific presentations of VABYSMO
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69155001
US	FDA, National Drug Code	50242-096